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BACKGROUND. Because of treatment-related toxicity, research is increasingly being
focused on long-term sequelae secondary to hematopoietic stem cell transplanta-
tion (HSCT) in survivor populations.
METHODS. This study describes the incidence of auditory, sensory, motor, and
visual impairments, including cataracts, among 235 individuals who were treated
with HSCT during childhood or adolescence. Outcomes were compared with 705
siblings of childhood cancer survivors. Participants completed a survey with ques-
tions on posttransplant organ system impairments. Approximately half of survivors
were transplanted when younger than 10 years of age. The median length of
followup was 11 years.
RESULTS. The cumulative incidence of cataracts was 36% at 15 years post-HSCT,
although cataracts occurred only in those who received total body irradiation as an
HSCT conditioning agent or head irradiation before transplant. Persistent pain was
reported by 21% of survivors. Loss of hearing in one or both ears, and legal
blindness in one or both eyes, each occurred after transplant in 2% of survivors.
Occurrences were uncommon, but survivors were 4.3 times (95% confidence
interval [CI]: 2.0 –9.4) more likely to report coordination problems, 7.7 times (95%
CI: 3.2–18.5) more likely to report chewing or swallowing problems, and 3.5 times
(3.5; 95% CI: 1.6 –7.9) more likely to report muscle weakness than those in the
comparison group. Muscle weakness was strongly associated with positive history
of chronic graft-versus-host disease.
CONCLUSIONS. Increased risks were found for motor impairments, hearing loss,
vision loss, and persistent pain among study participants. Cataracts were a fre-
quent adverse effect, suggesting that close monitoring with appropriate interven-
tion for preservation of vision, particularly among those who received total body
irradiation, should be a primary goal in survivors of HSCT performed in childhood.
Cancer 2006;106:1402– 8. © 2006 American Cancer Society.
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Combined data from the International Bone Marrow Registry andthe Autologous Bone and Marrow Transplant Registry show that
approximately 50,000 hematopoietic stem cell transplantations
(HSCTs), including 5,400 recipients age 20 years or younger, are
performed worldwide each year.1,2 A variety of life-threatening child-
hood conditions are now successfully treated with HSCT, as either a
first-line or rescue therapy. Improved survival rates have sharpened
the need for research that is focused on adverse medical effects that
may emerge or persist many years after treatment.2,3 Long-term con-
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sequences, both medical and psychosocial, may result
from the underlying disease process, the treatments
used, the acute toxicity and sequelae from treatment,
and from associated conditions that emerge long after
treatment and cure. With HSCT for malignancies and
hematologic disorders, where ablative chemotherapy
and often total body irradiation (TBI) are used as
conditioning modalities in preparation for infusion of
progenitor cells, the opportunity for late adverse ef-
fects is particularly evident.4 – 6
Patients who receive HSCT from an allogeneic
source are also at risk for the development of acute
(within 100 days of transplant) and chronic (after 100
days) graft-versus-host disease (GVHD) in which anti-
genic disparities between the donor T-lymphocytes
and recipient cells result in tissue injury, often severe,
involving the skin, and/or liver, and/or gastrointesti-
nal tract.4,7 Cyclosporine A is a drug commonly used
to treat chronic GVHD. Neurotoxicity is a recognized
complication of cyclosporine A, and may include gen-
eralized seizures, occipital blindness, and hemipare-
sis. Magnetic resonance imaging (MRI) findings in
allogeneic recipients indicate hyperintensity lesions,
predominantly in the posterior cerebrum, with both
subcortical and cortical involvement, and cerebellar
lesions, suggesting vascular injury as a contributing
factor in the pathology of neurotoxicity.8 In another
study of adult recipients of allogeneic transplanta-
tion,9 the occurrence of microangiopathy after trans-
plantation, observed in seven of eight patients with
chronic GVHD evolving from acute GVHD, had an
unfavorable influence on neurologic status. Cyclo-
sporine treatment of longer than 6 months was also
associated with increased risk for neurologic sequelae
in that study.9
Most reports on long-term consequences of HSCT
have focused on transplants performed in adults, or
have incorporated results on children in a largely adult
cohort of survivors. Some of the consequences re-
ported after HSCT performed in childhood include
subsequent malignancies10 –12; pulmonary compro-
mise13–15; endocrine dysfunction, including hypothy-
roidism, gonadal failure, infertility, and growth atten-
uation16 –19; and functional limitations.20 Very few
studies have included evaluations of neurologic func-
tioning in long-term survivors of HSCT performed in
childhood. This analysis from the Bone Marrow Trans-
plant Survivor Study (BMTSS) describes the incidence
of cataracts and of neuromotor and neurosensory out-
comes among 235 individuals who were treated with
HSCT during childhood or adolescence, and compares




The BMTSS is a collaborative study between City of
Hope Cancer Center and the University of Minnesota.
The study was established in 2000 to evaluate health
outcomes in a cohort of children and adults diagnosed
with cancer or other life-threatening illnesses treated
with HSCT. Eligibility criteria for this analysis included
receiving HSCT between January 1, 1974, and Decem-
ber 31, 1998, at age 20 years or younger; surviving at
least 2 years after transplant and alive at interview
date; and ability to provide informed consent and
complete a questionnaire in English. The comparison
group for this analysis is composed of a sample of
siblings from a cohort of childhood cancer survivors21
who completed a questionnaire between 1996 and
2003 containing the same questions as those used in
this study. To form a near identical distribution of
demographic characteristics, comparison group par-
ticipants were frequency-matched to cases at a ratio of
3:1 and randomly selected from 3,845 eligible mem-
bers from within six age groups ( 10 yrs, 11–14 yrs,
15–17 yrs, 18 –29 yrs, 30 –39 yrs, 40 yrs or older), two
sex groups, and two broad race/ethnicity categories
(white, nonwhite). The percentage of parent respon-
dents was 33% for both the survivors and the compar-
ison group. The informed consent process and the
study protocols and documents were approved by the
Human Subjects Research Review Committees at the
two collaborating institutions.
Data Collection
Participants completed the BMTSS questionnaire, a
survey with questions on organ system impairments
including when the problem was first diagnosed by a
physician or other healthcare provider. Questions
were also asked on prevalent medical conditions,
medication use, health status, health behaviors, preg-
nancy history, demographic characteristics, socioeco-
nomic indicators, and insurance coverage. The BMTSS
questionnaire is identical to the survey developed for
use in the 14,000-subject Childhood Cancer Survivor
Study,22 with a few additional questions specifically
related to HSCT. The self-report BMTSS questionnaire
was evaluated for reliability on a random sample of
100 HSCT survivors. The agreement with medical
records was excellent (kappa  0.8) for musculoskel-
etal, cardiovascular, pulmonary, and endocrine im-
pairments. Agreement was moderate (kappa 0.4 – 0.7)
for second cancers, central nervous system disorders,
and eye problems.23
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Outcome Variables
Four general categories of neurologic impairments
were considered: auditory, visual, motor, and sensory.
Auditory impairments included the following medical
conditions: any hearing loss (hearing loss requiring a
hearing aid, or partial or complete deafness in one or
both ears), tinnitus, and persistent dizziness or ver-
tigo. Visual impairments included legal blindness in
one or both eyes, cataracts, and double vision. Motor
impairments included coordination difficulties (prob-
lems with balance, equilibrium or manipulation skills,
and tremors or movement disorder), problems chew-
ing or swallowing, and muscle weakness. Sensory def-
icits included a decreased or abnormal sense of touch
or feeling in hand, fingers, arms or legs, an abnormal
sense of taste or smell, and persistent pain.
Independent Variables
Transplant type (autologous or allogeneic), condition-
ing regimen (with or without TBI), and, among allo-
geneic recipients, past or present chronic GVHD (yes
or no) were considered as potential risk factors for
these analyses. Time since transplant, age at interview,
race/ethnicity, and sex were considered as possible
modifiers or confounders. Information on transplant
type, treatment, and GVHD was obtained from the
HSCT databases at each institution.
Data Analysis
The incidences of visual, auditory, sensory, and motor
impairments were identified by tabulating affirmative
responses to the associated questions presented in the
BMTSS questionnaire, but only if the participant re-
ported that the complication first occurred after the
transplant date. Two sample t-tests for continuous
variables, and chi-square tests for dichotomous vari-
ables, were used to compare differences between sur-
vivors and the sibling comparison group, and between
allogeneic recipients with or without chronic GVHD,
by sex, race, transplant institution, and age at inter-
view.
The incidence of each medical late effect was
compared between survivors and the comparison
group by calculating risk ratio (RR) and 95% confi-
dence intervals (95% CI) using generalized estimating
equations (GEE) with a Poisson distribution and a log
link.24,25 The factors used to select cases for frequency
matching, i.e., age group, sex, and race/ethnicity, were
evaluated as independent predictors of the outcomes,
and as possible confounders in the models. Reflecting
the successful frequency matching scheme, the
matching variables did not appreciably alter the risk
estimates, so they were not included as covariates in
the final models that compared incidence of impair-
ments between survivors and siblings of cancer survi-
vors.
In an analysis limited to allogeneic recipients
only, chronic GVHD status was evaluated in relation to
the outcome variables using generalized estimating
equations. These models were adjusted for age at
transplant, time since transplant, and sex. Race/eth-
nicity did not appreciably alter the estimates and was
not included in the reporting of results. Potential con-
founding by age at transplant, sex, time since trans-
plant, and chronic GVHD was examined by looking at
the strength and the precision of risk estimates in both
full and reduced models.
Cumulative incidence of cataracts, overall, by
chronic GVHD history, and by whether or not TBI was
used as a conditioning treatment, was calculated in a
competing risk analysis using the Markov Chain Ap-
proach of Aalen and Johansen.26,27 Wilcoxon signed
rank tests were used to compare cumulative incidence
rates by transplant type among survivors and by
chronic GVHD history among allogeneic recipients.




A total of 528 potentially eligible patients were identi-
fied at the two institutions. Of these, eligibility could
not be confirmed for 136 patients (25.7%) who were
lost to followup and could not be contacted. An addi-
tional 131 (24.8%) declined participation, and 26
(4.9%) had yet to complete the study questionnaire
and are considered passive refusals. The question-
naire was completed by 235 participants (157 survi-
vors and 78 parents of survivors), representing 45% of
those initially identified and 60% of those successfully
contacted. Participants were more likely than poten-
tially eligible nonparticipants to be female (44% vs.
34%, P  0.02), but did not differ statistically by race (P
 0.06), treatment institution (P  0.55), age at trans-
plant (P  0.42), transplant type (P  0.81), HSCT
conditioning regimen (P  0.19), or by history of
chronic GVHD (P  0.27). From the 3:1 frequency
matching strategy, data from 705 childhood cancer
siblings were included as the comparison group for
this analysis.
Participant Characteristics
The median age at survey completion was 21 years for
both the HSCT survivors (range, 5– 42 years) and the
comparison group (range, 5–50 years). Table 1 pro-
vides characteristics of the study participants. The
most common cancer diagnoses were acute myeloid
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leukemia (30%) and acute lymphoblastic leukemia
(26%), and the most common conditioning regimen
was a combination of TBI with chemotherapy (75%).
Approximately half of the survivors were transplanted
when younger than 10 years of age. The median length
of followup was 11 years (range, 2–28 years) and 82%
had survived at least 6 years since their transplant
when interviewed.
Outcome Measures
Hearing loss in one or both ears was reported by 2.6%
of survivors (RR: 4.5; 95% CI: 1.3–15.9), and persistent
dizziness was reported by 3.4% (RR: 4.0; 95% CI: 1.4 –
11.5), versus 0.6% and 0.8%, respectively, in the com-
parison group (Table 2).
Legal blindness in at least one eye was reported by
2.1% of survivors versus 0.7% of the comparison group
(RR: 3.0; 95% CI: 0.9 –10.4). Occurrence of a cataract
was reported by 38% of HSCT survivors, compared
with 0.1% of the comparison group (RR: 270; 95% CI:
38 –1937; Table 2). Among the 90 survivors with a
cataract, 86 (96%) had received TBI as part of their
conditioning regimen and 77 (86%) received an allo-
geneic transplant. The four patients with a cataract
who were not exposed to conditioning TBI had been
treated with radiotherapy to the head/neck region
before HSCT. The cumulative incidence of cataracts,
as shown in Figure 1, was 21% at 5 years posttrans-
plant, 32% at 10 years, and 36% at 15 years after HSCT.
Survivors of allogeneic HSCT were more likely to re-
port a cataract (cumulative incidence of 40% at 15
years), when compared with survivors of autologous
HSCT (cumulative incidence of 21% at 15 years, P
 0.009). Furthermore, among survivors of allogeneic
HSCT, those with chronic GVHD were more likely to
report a cataract (cumulative incidence of 46% at 15
TABLE 1




Group (N  705)
n (%) n (%)
Gender
Male 131 (55.7) 393 (55.7)
Female 104 (44.2) 312 (44.2)
Race/ethnicity
White 199 (84.7) 597 (84.7)
Hispanic 18 (7.7) 53 (7.5)
Other 18 (7.7) 55 (7.8)
Treating institution
City of Hope 58 (24.2) NA
University of Minnesota 177 (75.7) NA
Age at interview
 18 yrs 78 (33.2) 234 (33.2)
18  yrs 157 (66.8) 471 (66.8)
Age at transplant
 5 yrs 61 (25.9) NA
5–9 yrs 57 (24.2) NA
10 yrs 117 (49.8) NA
Time since transplant
2–5 yrs 43 (18.3) NA
6–10 yrs 81 (34.5) NA
11 yrs 111 (47.2) NA
Primary diagnosis
Acute lymphoblastic leukemia 62 (26.4) NA
Acute myeloid leukemia 70 (29.8) NA
Aplastic anemia 31 (13.2) NA
-Thalassemia major 1 (0.4) NA
Chronic myeloid leukemia 15 (6.4) NA
Ewing sarcoma 5 (2.1) NA
Fanconi anemia 7 (3.0) NA
Hodgkin disease 9 (3.8) NA
Myelodysplastic syndrome 9 (3.8) NA
Neuroblastoma 16 (6.8) NA
Non-Hodgkin lymphoma 7 (3.0) NA
PNET or Medulloblastoma 2 (0.8) NA
Wilms tumor 1 (0.4) NA
Transplant type
Autologous 58 (24.7) NA
Allogeneic 177 (75.3) NA
Conditioning regimen
Chemotherapy 59 (25.1) NA
Total body irradiation and
chemotherapy 176 (74.9) NA
NA: not applicable.
TABLE 2
Auditory, Visual, Motor, and Sensory Impairments among Childhood






RR (95% CI) Pn (%) n (%)
Auditory impairments
Hearing loss in one or
both ears 6 (2.6) 4 (0.6) 4.5 (1.3–15.9) 0.02
Tinnitus 9 (3.8) 16 (2.3) 1.7 (0.7–3.8) 0.21
Persistent dizziness 8 (3.4) 6 (0.8) 4.0 (1.4–11.5) 0.01
Visual impairments
Blind in one or both eyes 5 (2.1) 5 (0.7) 3.0 (0.9–10.4) 0.08
Cataract 90 (38.3) 1 (0.1) 270 (38–1937)  0.001
Double vision 2 (0.9) 3 (0.4) 2.0 (0.3–12.0) 0.45
Motor impairments
Coordination problem 16 (6.8) 11 (1.6) 4.3 (2.0–9.4)  0.001
Swallowing problem 18 (7.7) 7 (1.0) 7.7 (3.2–18.5)  0.001
Muscle weakness 13 (5.5) 11 (1.6) 3.5 (1.6–7.9) 0.002
Sensory impairments
Abnormal sense of touch 11 (4.7) 13 (1.8) 2.5 (1.1–5.7) 0.02
Persistent pain 49 (20.9) 69 (9.8) 2.1 (1.5–3.1)  0.001
Abnormal sense of taste
or smell 10 (4.2) 2 (0.3) 15.0 (3.3–68.4)  0.001
RR, risk ratios with 95% confidence intervals. HSCT, hematopoietic stem cell transplantation.
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years) than were those without a history of chronic
GVHD (cumulative incidence of 38% at 15 years, P
 0.03). When the analysis was limited to the 176
survivors who received conditioning TBI, however, no
differences in cataract incidence was observed by
transplant type (P  0.47) or by chronic GVHD history
(P  0.43).
Motor impairments represented the highest inci-
dence of reported outcomes among survivors, except
for cataracts, ranging from 7.7% for swallowing prob-
lems to 5.5% for muscle weakness (Table 2). Survivors
were 4.3 times (95% CI: 2.0 –9.4) more likely to report
coordination problems and 7.7 times (95% CI: 3.2–
18.5) more likely to report chewing or swallowing
problems than were members of the comparison
group. Muscle weakness was also considerably more
common among survivors than in the comparison
group (RR: 3.5; 95% CI: 1.6 –7.9).
Persistent pain was the most common sensory
impairment among both HSCT survivors (20.9%) and
the comparison group (9.8%, RR: 2.1; 95% CI: 1.5–3.1).
Survivors were 2.5 times (95% CI 1.1–5.7) more likely
to report an abnormal sense of touch and 15.0 times
(95% CI: 3.3– 68.4) more likely to report an abnormal
sense of taste or smell than was the comparison group
(Table 2).
Outcomes and Chronic GVDH
Among the allogeneic transplant recipients, there
were no discernable differences in the proportions
with a history of chronic GVHD who reported audi-
tory, visual, or sensory impairments when compared
with those without a history of chronic GVHD (data
not shown). A strong association was observed, how-
ever, with muscle weakness, as reported by 19.6% of
allogeneic recipients with a history of chronic GVHD
history versus 2.3% of those without a history of
chronic GVHD (RR: 10.6; 95% CI: 2.5– 45.8).
DISCUSSION
With the exception of cataracts and persistent pain,
our followup study of persons treated with HSCT as
children or adolescents found a relatively low inci-
dence of reported impairments to auditory, visual,
motor, and sensory systems. This is encouraging for
the increasing number of children who undergo and
survive stem cell transplantation for life-threatening
disorders. Loss of hearing in one or both ears, and
legal blindness in one or both eyes, each occurred
after transplant in 2% of the survivors in our study.
These outcomes can have a very significant impact on
an individual’s life, so the 3– 4-fold elevated risks for
hearing or vision loss, albeit low in actual frequency of
occurrence, should be considered when discussing
with patients and parents the need for posttherapy
surveillance and screening of potential long-term se-
quelae. Retinal complications after bone marrow
transplantation, likely from multifactorial causes, have
been described previously and warrant careful long-
term monitoring.28,29 Consistent with our study re-
sults, deterioration in hearing after pediatric HSCT
was recently reported in a clinical study of 45 chil-
dren.30 Platinum compounds used in some chemo-
therapeutic regimens, particularly cisplatin, are well-
established ototoxic agents31,32 and may be
etiologically related to the hearing loss we observed in
our study. Motor impairments, notably problems
chewing and swallowing, muscle weakness, and coor-
dination problems were reported by 5– 8% of our
study population. Unfortunately, we were not able to
evaluate the severity of these problems or the associ-
ated impact on the quality of life and functional abil-
ities of the survivors with these impairments. These
findings provide justification for several areas of fur-
ther research by directed clinical study to better elu-
cidate severity and functional impact of these long-
term sequelae.
Also important is the report of persistent pain by
21% of survivors, a twofold (95% CI 1.5–3.1) increased
risk over that of the comparison group. Because pain
may be an early indicator of disease recurrence or a
new malignancy in these patients, and effective treat-
ment options for idiopathic chronic pain are available,
pain evaluations are warranted in transplant followup
settings and, longer-term, in primary care settings.
The high frequency of cataract occurrence among
those who receive TBI as an ablative treatment pre-
ceding stem cell infusion is important to note for
planning of followup care. Although steroids are
FIGURE 1. Cumulative incidence of cataracts with 95% confidence bounds
among childhood HSCT survivors.
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known cataractogenic agents,33 and often incorpo-
rated into treatment of hematologic malignancies and
chronic GVHD,7 we did not find any cases of cataract
among study patients who were not treated with TBI
or head radiation pre-HSCT. In a followup series of
197 HSCT patients (median age, 25 years), Tichelli et
al.34 found results similar to ours, in that chronic
GVHD did not influence the rate of cataract occur-
rence, a high rate of cataracts was observed among
those who received TBI, and only 1 of 33 patients who
received chemotherapy without TBI developed a cat-
aract. A recent retrospective analysis of 188 children
who received HSCT found that eye shielding during
TBI conditioning increased the latency time of cata-
ract formation and decreased the severity of cataracts
without increasing risk for central nervous system
(CNS)-related recurrence,35 thus illustrating an ap-
proach that could be considered for reducing cataract
risk.
The results of this study should be interpreted
with an appreciation for certain limitations of this
observational study design. First, if participants dif-
fered from that of eligible nonparticipants in ways
important to our outcome measures, then our fre-
quencies and risk estimates may be biased. Our com-
parison of treatment-related factors between partici-
pants and nonparticipants suggests that there are no
obvious problems with our study population, but we
cannot rule out the possibility. Second, our outcome
measures are based on self-report, from the patient or
his or her parent, and we did not confirm the provided
information in a clinical setting. Our previous evalua-
tion of these methods in HSCT survivors showed rea-
sonably reliable agreement between medical records
and self-reported impairments23; however, misclassi-
fication of outcome with self-report is certainly a pos-
sibility. It should also be noted that, despite our in-
quiries about date of onset, we could not definitively
establish whether the impairments reported in this
study, including hearing loss, vision loss, and persis-
tent pain, can be attributed to damage from the un-
derlying disease, any therapies before HSCT, or the
HSCT treatment course.
In summary, with the exception of cataract occur-
rence, relatively few neuromotor and neurosensory
problems were reported by survivors of HCT per-
formed in childhood. We did, however, find increased
risk for motor impairments, hearing loss, vision loss,
and persistent pain, suggesting the need for further
investigation to understand the causes. As described
in adult HSCT patients, cataracts are a frequent ad-
verse effect of HSCT performed in childhood, occur-
ring in 38% of our study population during the fol-
lowup period. Close monitoring with appropriate
intervention for preservation of vision, particularly
among those who received TBI, should be a primary
goal in survivors of childhood HSCT.
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